Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a clinical collaboration to evaluate combinations of Revolution Medicines’ investigational RAS(-ON) inhibitors with Summit Therapeutics’ ivonescimab in multiple solid tumor settings.

The collaboration will assess the safety and efficacy of these combinations in RAS mutant non-small cell lung cancer/NSCLC, pancreatic ductal adenocarcinoma/PDAC, and colorectal cancer/CRC. Under the agreement, Summit Therapeutics will supply ivonescimab for clinical research, while Revolution Medicines will serve as the study sponsor. Both companies will retain commercial rights to their respective compounds.

Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors

A researcher poring over test results, illustrating the breakthrough potential of biotechnology.

The agreement is mutually non-exclusive, allowing each company to pursue additional partnerships. Revolution Medicines will contribute 3 of its clinical-stage RAS(-ON) inhibitors to the collaboration: daraxonrasib (RMC-6236), which is a multi-selective inhibitor; zoldonrasib (RMC-9805), which is a G12D-selective inhibitor; and elironrasib (RMC-6291), which is a G12C-selective inhibitor.

Revolution Medicines Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company.

While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.